Welcome to the 2026 edition of Jefferies Healthcare Conference here in London. It is great to see so many people in the room. My name is Ben Jackson. I am from the European BioPharma team here at Jefferies. I am joined today by Adam Steensberg, CEO of Zealand. We are going to have a little fireside chat and jump straight in.
Thank you so much for your time today, Adam. I guess the first thing I want to address, we are coming up to that one-year mark now of the Metabolic Frontier strategy. What are the big things that you have taken away from that year, and what would you like to highlight to people? Then we will jump straight into a little bit more detail.
Yeah, I am pleased to be here. You are right, we are around a year into our, since we announced our 2030 Metabolic Frontier strategy. I must say that I am immensely proud to share also the progress that we have seen since. I think it is really demonstrating Zealand at its best. We have delivered big time on our late-stage assets in obesity, both with the petrelintide together with Roche, our partner Roche, and then Boehringer.
We are now seeing a very strong profile, we believe, around survodutide, really, as that has read out during the year. Another aspect of the Metabolic Frontier 2030 is, of course, building what comes next. There we have managed to open our new research site in Cambridge, Massachusetts, earlier in September. We have announced several partnerships to help kind of expand our research efforts, and really to deliver on this overall vision and ambition to have 10 new clinical programs over this period, focusing on metabolic health.
Of course, all this being kind of led by our late-stage assets with Boehringer and with Roche. Next to that, we also are delivering on our rare disease late-stage programs. We just had an approval of glepaglutide announced Friday, which we are super excited to see the first kind of novel therapy being approved for patients with short bowel syndrome in Europe. We are going to see a good progress in the phase III study that should facilitate an FDA approval submission sometime later.
For CHI, our other rare disease opportunity, we will submit to FDA later this year. Significant progress on all fronts, and really, I would say, delivering big time on this ambition to become a generational biotech that really will become a leader in metabolic health in the future.
That's a great summary. I guess if we start then on petrelintide and amylin, I think that's a good place to go. We've now seen results from ZUPREME-1 and ZUPREME- 2. What have those taught you about the potential profile that ultimately you and your partner can aim for in phase III? What should we be looking out for on the way in terms of those aspects on the efficacy or tolerability side versus what we see today on the market?
Yeah, thanks for that question. We are actually extremely pleased with how the data has read out. We think as this space, the weight loss space, starts to mature, and we're already starting to see the first signals, and I would also say external validation of this hypothesis, that the future battlefield is not going to be around who delivers the highest weight loss. The future battlefield for, or you may say the future winners in this space, is going to be around how can you deliver the weight loss that patients are looking for in the most tolerable way?
How can you develop a drug that is easy to start on, but as importantly, easy to stay on? That will unlock the opportunity to actually address the health aspects of living with obesity, but it will also unlock the value because, of course, if people stop taking therapies, there's little value in it. With petrelintide, we do think we have a product, when we look at the data, that really delivers the double-digit weight loss that most patients are asking for.
Then with the tolerability profile, in essence, it has been like placebo-like tolerability that we have seen thus far, which is in contrast to the GLP-1 class. I would also say when we look at the data, I think we may be starting to see some differences within the class, where we have constantly seen this also with the latest dataset in type 2 diabetes, that we can actually deliver the same tolerability profile.
Then also, you could potentially expect quite similar weight loss experiences regardless if you have diabetes or not. Again, a product which could be a logical start for the most people when they start a weight loss journey, easy to start on and easy to stay on. That's the winning recipe for the future, we believe.
And I guess over the last maybe two years, we've sat up here and discussed how you eventually potentially position amylins, whether we think about them as more of an induction side, a combination side, a maintenance side. We've had all those different words thrown around. I guess, how do you envision amylins potentially being positioned in this market ultimately when they come to market? And how early do you have to start thinking about that? Do you have to design the phase IIIs to try and get them there? Any thoughts on that?
It's, of course, always difficult to predict about the future, but very often a good place to look is actually in the past. Are there other therapeutic areas where you can actually have some past experience that you can build your future predictions on?
And if you look into any other chronic therapy area, what we have seen is that once you have more tools, once you're not only left with one or two instruments to manage a disease, then what you will see as a first-choice therapy actually always have become the most tolerable approach that gives you a reasoned chance to believe that you will get a clinical response. So instead of viewing an obese patient as a very static situation, once you have more tools, you have to view people through the lens of a life they want to live.
And very often, when they have choices, you would choose the most pleasant way to try to achieve what you aim for. If you then need more, then you will start to add combinations or change to something that can be more cumbersome to be on, but potentially also deliver more of that outcome, in this case, weight loss. So we think you need to start to really view the future market where there are more choices through the lens of a journey from that individual patient.
And that means, in our book at least, if you look into hypertension, into diabetes, into dyslipidemia, we have always seen the most easy to start on, easy to stay on solutions to actually be introduced first.
Yeah. Very clear. And I guess recently we had the ZUPREME-2 readout too. So what were the major things you'd point to from there in terms of learnings? And then ultimately, how do you think about amylin in this diabetic space? Is it something that goes towards pre-diabetic patients or combination approaches? How do you envision that playing out?
If you think about amylin biology, in contrast to the GLP-1s, which probably have most of the effect in diabetes through their ability to release insulin, stimulate insulin production, then in contrast to that, amylin more works on insulin sensitivity. Early onset or recent onset diabetes is a very logical place for an amylin analog, because history at least has shown us that it's a better approach to actually try to work on insulin sensitivity rather than drive increased insulin production.
I would say early in the aspect of diabetes development, or you could even think about diabetes prevention, amylin biology lends itself extremely well to that. The other thing we observed with the ZUPREME-2 data, that we didn't see the same penalty in weight loss that we see with the GLP-1s going from patients without diabetes to patients with diabetes, where we often see a 30%-50% reduction in efficacy with the GLP-1s. We didn't see that in this situation.
Of course, again, if you think about a patient who lives with diabetes who would be really interested in weight loss, amylin looks like a very attractive opportunity, and in particular with petrelintide, where we start to see that you don't get that penalty which we have seen with other modalities and perhaps also with other amylins in the class.
I think that's a really good picture of the amylins as monotherapies, but obviously you and your partner are also looking at combination approaches with Roche's incretin as well. Ultimately, what is the aim there to develop? Is it something where you can change the balances of GLP-1 and amylin? How do you see that going forward? We're about to see a phase II initiation. When could we see those results?
Yeah, no, we're super excited about this opportunity to combine petrelintide with enicepatide, the GLP-1/GIP molecule that Roche is developing also as a monotherapy. We actually think it looks like a very, very strong GLP-1/GIP from the efficacy and solubility data that we have seen thus far.
Of course, the combination of such a molecule between an amylin and a GLP-1/GIP, in our book, is really the most promising combination we are looking at the moment, to achieve that highest weight loss or potentially address people who live with overweight and obesity and increased risk of or increased established diseases such as diabetes and other comorbidities that follows along living with obesity for a long time.
The combination, and this is where I think when we start to look into the future in a more complex treating universe, you will start to see that fewer and fewer companies are running after that weight loss Olympics, trying to get the highest weight loss number with a single modality molecule. If you need that highest weight loss, you have to think about combinations, and that is where this is really a strong opportunity, what we have here.
Timelines, we are going to start the study very, very soon. I expect to start it within weeks, as we have guided in this quarter. That should be running, and we, of course, together with Roche, has a keen focus on speed to get this product forward as well.
Clear. That is a good picture on petrelintide, but as part of the Metabolic Frontier strategy, are there more amylins that potentially could make way into the clinic, either as different routes of administration, a small molecule? How much of that plays into your thinking at the moment?
Yeah, we have communicated for a long time, we are leading this. We believe we are leading in the amylin space and really working with one of the most differentiated potential leading amylins with this first-choice opportunity with petrelintide. But we also have an aspiration and continue to innovating in this space, and that would be amylin combination, but of course, also other ways of administering the product.
So we, I would say, if you ask our CSO, Utpal, then he is spending quite a lot of time making sure that we will also have the next winners to continue to build on this market opportunity. We really see amylin as a foundation in the future for most patients when they start a weight loss journey, and we want to have solutions on all aspects. But of course, they are a few years behind what we do with petrelintide right now.
You, of course, receive royalties on cagrilintide, where we have had some recent news flow in and around the SYNCHRONIZE-CVOT study. We saw there that confirmed the cardiovascular profile ready for filing next year under Boehringer. Was there anything in that data set that particularly surprised you and increased the confidence around that royalty stream that you should receive?
We were actually super pleased with the data set. I don't know if you remember back, there's been concerns around adding glucagon to such a molecule. I mean, I think people understand the benefit that when you add glucagon, you can really target the weight loss to the liver and the intestines. We actually, if you think about the weight loss that we have seen with survodutide so far, it's mainly driven by weight loss from the liver and from the intestines.
And we have seen probably the best muscle preservation ever with only 10% muscle waste compared to up to 30% with other modalities. So it's really a product that delivers, I believe, the weight loss that patients are looking for in the sense of targeted weight loss in the intestine, in the liver. People have also speculated, could glucagon pose a risk to cardiovascular safety because glucagon increases heart rate and other things?
With the data we saw right now, it was a non-inferiority study, but we still had hazard ratios of between 0.84 or 0.9, which suggests, at least indicating definitely safety, but also basically hazard ratios that are in line with what we have seen from the GLP-1 molecule. So it really cleared that discussion, I would say, for this specific molecule, for survodutide.
And remember, we specifically designed survodutide so it's not too active on glucagon. It's eightfold more active on GLP-1. So with this molecule, I believe Boehringer have made a major clearance with this data set.
Clear. We've also seen SYNCHRONIZE-1 and SYNCHRONIZE-2 now, so two more studies. I guess when you look at that data set, a lot of people focused in around the tolerability. There were some decent explanations, certainly at ADA, about why that happened.
Do you want to remind us, why do you think we observed that kind of tolerability profile, and when is the next readout that you're looking for to understand what actually is the underlying tolerability profile, perhaps in the real-world setting, or a dose scheme that represents the real-world setting, I should say?
Absolutely. You can say you're completely right that there was a lot of focus on the dropouts in that study, which was up to 20%, around 20% dropout in the study. I actually think Boehringer and the investigators, when they presented the data, did a very, very good job at explaining that their observation is it was due to a very strict titration protocol where they basically didn't allow the patients to do flexible dosing. They also actually asked patients to stay at the highest doses even though they would like to reduce them.
And we know for a fact that many patients, if they have too much weight loss, they actually like to reduce the dose of a GLP-1. So the titration protocol was simply too tight and too fixed. Boehringer did change the titration protocols in December of 2025, I think, for all their ongoing studies, but it was too late to affect the outcomes of these studies. The LIVERAGE study, which is in MASH patients, 1,800, that will read out next year, there, the changed titration algorithm had deep impact, at least according to Boehringer and to the investigators.
If you hear Boehringer talk and the confidence with which they address this issue, they are very confident that they have managed the tolerability profile with that changed titration scheme. You know what? If you think into the real-world use of GLP-1s, prescribers and patients don't follow the titration that you see today. If they were, you would see the similar rates of dropouts. It would not be because we know we have to individualize how you dose a GLP-1 because they are highly intolerable in general for many patients.
Perhaps the one data set that we don't talk enough about is the SYNCHRONIZE-MASLD results that we got at the same time too. So when you reflect on those, how much in that mind does that de-risk the asset into the LIVERAGE trials, which perhaps are the next big thing that we're waiting for on our side?
There's that study, of course, where we showed six out of 10 patients had a complete normalization of liver fat. But there's also the phase II study that read out a few years back, which really suggests that with survodutide, we could have a product that have a deep impact on MASH state. Remember, Boehringer is not only doing a study in F2 and F3 patients, but also the most diseased cirrhotic patients, 1,500 patients too.
That again highlights their strong belief that likely this molecule could also do something about the cirrhotic patients. So I would say this data set is, of course, extremely important for the whole profile of survodutide in our minds, but it goes beyond just MASH and the opportunity to treat MASH. It speaks directly into this observation that 75% of people who live with obesity and overweight, they have excessive fat in the liver, and 35%, they have MASH.
The prevalence of people living with obesity that also have MASH is significantly higher than if you take cardiovascular disease, which is only around 10%, or diabetes, which is only 20%. Here you have 35%.
If you think about the messaging for why would you use survodutide to help with a weight loss, well, you would do that because it's targeting the weight loss to the liver fat and the intestinal fat while you preserve the muscle. It's a very, very strong narrative for this molecule. Who would not prefer to lose belly intestinal fat over muscle? That's what we have seen with survodutide being able to deliver.
Very exciting. Exciting to see what happens with that next year as well. We'll be keeping a keen eye. I guess if we move away from obesity then and go into ZP9830, the Kv1.3 ion channel blocker. What is the expected potential or opportunity you're pursuing with that molecule, and where do you intend to take it from here?
It's a super interesting opportunity. Of course, you could argue it's a little bit outside the scope of the Metabolic Frontier 2030 because it targets a broad autoimmune opportunity where I guess you could think about up to 80 different diseases that this molecule could potentially play a role in if it works the way we hope, representing 8% of the US population. It's in phase I. We have completed the phase Ia and phase Ib exposure into healthy volunteers.
We have an ongoing phase Ib study in patients who lives with plaque psoriasis. We anticipate to start another phase IIa study in another autoimmune disease later next year. To really, I would say, the way we should think about the target right now is that we are trying to explore it in different indications where we can learn more about how it could potentially affect disease stage in humans, because the translation from animal models into human disease is not always the best in autoimmune diseases.
You need to get into human disease situations to better understand this molecule or the potential of the molecule. We are trying to target, you can say, diseases where we know specific immunological pathways play a specific role, and then do perhaps more studies to really understand where to take this ultimately into phase III and to the market if it's successful. But we are pleased with what we're seeing so far.
Good. Exciting. You obviously chose psoriasis as the first indication to pursue in phase Ib. Perhaps just a little bit more on why psoriasis, and then where do you have, or what will you be benchmarking that to, given it's quite a short study?
Yeah, it's a short study, eight weeks. For us, it's also an opportunity to look for an early efficacy readout. I mean, of course, we understand that it has to be, I would probably argue, unexpectedly good data in order to have a strong commercial opportunity in psoriasis.
But it's a good proof of concept opportunity that we are pursuing. Then with the next indication we're going for, perhaps the commercial potential is even larger, and so be it with the next ones as well. So for us, it's an opportunity to understand the molecule and then ultimately broaden out the opportunity into disease stage where there's also a strong commercial opportunity.
When could be the right time to partner an asset like this? It's always the question that you can't answer now, but I'm going to ask it anyway.
No, but you're absolutely right. For us, it's going to be a balance between having generated enough data to make it an attractive value proposition to a partner, but also getting a partner on board early enough so we can go as broad as possible and as fast as possible. We recognize that moving into immunology is a complex clinical situation where organizational know-how is beneficial in clinical development. So, let's see when the time is right, but it's an opportunity which we think is great.
I would also say, if I should just draw one kind of link into the Metabolic Frontier 2030 strategy, of course, there is opportunities to also consider combining KV1.3 with a weight loss medication to really address not only the energy, but also the underlying inflammation you often have in this metabolic disturbed situation. That could be an interesting partner structure here.
Got it. The rare disease assets, we cannot forget those as well. We got some updated news on glepaglutide Friday even, the time flies. Can you remind us where you are in terms of thoughts about partnering those, and would you consider launching in the absence of a partner initially?
With the glepaglutide, which is now approved in Europe and in a large phase III study to support a US registration application, we see an opportunity for more than a decade to introduce a new medicine to patients who live with short bowel syndrome and who are in deep need of new modalities. There is only one product on the market today, Gattex, which I think is generating around $1 billion in sales, but it is less than 20% of the eligible population who is on treatment. We need new treatment options for these patients.
With glepaglutide, not only do we think we have a very, you can say, beneficial way of administration in an auto-injector and simple, instead of having to mix the product every day, but also very strong efficacy claims around the molecule with 14% of patients weaning off parenteral support, which is the ultimate goal for these patients. Imagine if you were hooked up to an infusion line for 24/7 and suddenly you are not dependent on that anymore. What freedom does that bring to your life?
There we have very strong data. Of course, on the back of this approval and also the positive recommendation by CHMP a few months back, we have intensified the discussions around glepaglutide and a potential partnership. It is a highly attractive commercial opportunity. There's a lot of rare disease assets, both smaller and large, companies, both smaller and larger, mid-size, who see this as a very attractive opportunity.
Same goes for CHI, where we anticipate to submit the NDA to FDA later this quarter, with a potential approval next year. We also are engaging in partnership discussions on that front. It's a smaller opportunity. It's an ultra-rare indication, and there you could probably easily argue, yes, Zealand could do it ourself. Of course, we are making all the preparatory steps to do so.
From a strategic point of view, our preferred scenario is to partner this in the sense that we can double down and focus our commercial efforts on a go-to-market with petrelintide in our partnership with Roche and Genentech.
If we switch from commercial stage down to early stage, you've signed a couple of deals now on early-stage research, for example, with OTR. How are they progressing, and when do you think we could see the first of those assets eventually emerge into the clinic?
Yeah. Our CSO here taught me a very strong way of communicating around that, because every time I ask him, "When can I expect this?" He just say, "On a Monday," but he doesn't commit to more than that. Anyway, yeah, I would say we see very strong progress across the early-stage assets. Remember, Utpal joined us one and a half year ago from Lilly, where he was leading small molecule drug discovery and had also been playing other roles over the years, many years he spent with Lilly.
He has come in, and in those 18 months, managed to not only get even more energy into the already energetic research site in Copenhagen, also starting a site in Boston. So we can now actually work with modalities beyond peptides into small molecules, siRNA, larger proteins.
We did a partnership with OTR last year in China on small molecules up to three targets, and we did one a month ago with Generate Biomedicines on larger complex multimodality structures that can target more receptors at the same time. Those partnerships are progressing with speed, especially, I would say, now we are a year into the partnership with OTR. We are extremely pleased with the speed with which they move forward and see some good progress around some opportunity. I will not commit to specific timelines yet.
Totally reasonable. My last question then, it's a tricky one to answer in the 40 seconds we've got left, but how meaningful in your seat do you think that the deployment of AI amongst your research and development efforts will be now, and how much more will it give you going forwards from today?
I would be probably a little bit of an outlier as a CEO if I said that AI was not going to be important for my business or any businesses. Of course, it will be hugely impactful. I think where we will see the most impact early on is on speed, also in research, how you can set up your lab so you can actually test and make sure you have testing cycles running much, much faster, and of course, also have AI inform you around choices as you go. We are building the lab.
The building in Boston is going to be very AI and data-centric, so it can run much faster cycles, and it's a big part of our commitment to actually getting from idea to clinic, being among the fastest in our industry to apply AI to that.
Similarly, AI has already installed a lot of efficiencies in development. If I can just take you one step further in the value chain into commercial and manufacturing, I actually think that's where we're going to see some of the deepest impacts into our businesses, where we have historically, as smaller companies, had to focus our efforts into the early stage of the value chain.
I think with data and AI, that now gives companies like Zealand a significant opportunity to go commercial into opportunities that would otherwise have been impossible just a few years back. We see in the U.S. unicorns, $1 billion companies in our space of two people, because they leverage data and AI. That's probably where I think AI will have the deepest impact on the biotech industry. That is the opportunity to actually follow your molecules longer.
On the target discovery, my own opinion there is it's still strongest around known biology, so you can get ideas around what is already known, but you will not get out to the It will not be very good at coming up with the crazy new ideas never seen to this world before yet.
Very insightful. Look, Adam, thank you so much for your time. Thank you all for listening. It has been a pleasure. We will see you again soon in an upcoming presentation. Thank you, Adam.